ClinicalTrials.gov Identifier NCT00608764

This nationwide multicenter study aims to identify the genetics behind why some smokers get COPD and others do no not. The study is still open to enrollment but only participants who have never smoked.

Embark

ClinicalTrials.gov Identifier NCT06883305

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving inhaled maintenance therapy and having had at least 2 moderate, or 1 severe, COPD exacerbations in the 12 months prior to Visit 1. Subjects will receive monthly subcutaneous injection of one of two different doses of tezepelumab, or placebo, with a maximum treatment duration of 76 weeks and a minimum of 52 weeks. The study also includes a off-treatment safety follow-up period of 12 weeks.

NMF Study

We are currently looking for volunteers for a research study to better understand how fatigue of the breathing muscles alters leg muscle performance and how this affects people with or without chronic obstructive pulmonary disease (COPD) and their ability to exercise.

PRISm

We are currently looking for volunteers for a research study that we are conducting to better understand a pulmonary condition termed Preserved Ratio Impaired Spirometry (PRISm) and how this affects people’s everyday life and their ability to exercise. People with PRISm have abnormal lung function tests, do not have Chronic Obstructive Pulmonary Disease but do have shortness of breath during physical activity.

Wearables 2

Our research teams at the Lundquist Institute at Harbor-UCLA Medical Center and Caltech, are testing an experimental skin sensor to see if it can measure markers of lung infection without taking a blood sample. We are seeking your participation in our research to help develop this COPD flare-up early warning system.